Flavia Hoyte
YOU?
Author Swipe
View article: Reply to Liu <i>et al.</i>, Zhou <i>et al.</i>, and Dong <i>et al.</i>
Reply to Liu <i>et al.</i>, Zhou <i>et al.</i>, and Dong <i>et al.</i> Open
International audience
View article: Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach
Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach Open
T2-targeting biologics have utility in the management of asthma with low T2 involvement, but more effective therapies are needed. Further research is warranted to identify specific pathogenic pathways at the lower end of the T2 spectrum th…
View article: Asthma remission in the context of other immune-mediated diseases
Asthma remission in the context of other immune-mediated diseases Open
View article: Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction
Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction Open
The introduction of biologics, such as benralizumab (an anti‐IL‐5 receptor α humanised monoclonal antibody), has made remission a feasible goal for patients with severe eosinophilic asthma (SEA). However, there are remaining research gaps …
View article: ”Treat-to-Target”: A Call for Earlier Targeted Intervention in Asthma
”Treat-to-Target”: A Call for Earlier Targeted Intervention in Asthma Open
The treat-to-target approach is a concept that has been successfully implemented in many disease areas such as rheumatoid arthritis and cardiovascular disease and more recently is being discussed in asthma. Currently, asthma management is …
View article: Real-World Biologic Use Patterns in Severe Asthma, 2015–2021: The CLEAR Study
Real-World Biologic Use Patterns in Severe Asthma, 2015–2021: The CLEAR Study Open
Switching or stopping biologic therapy was associated with worse clinical outcomes than continuing the initial therapy.
View article: Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps Open
View article: Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma Open
Background To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials. Aim To e…
View article: Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”
Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry” Open
View article: Skin Test (ST) Responses to Seasonal and Perennial allergens in a Broad Asthma Population Across Severities and Comorbidities
Skin Test (ST) Responses to Seasonal and Perennial allergens in a Broad Asthma Population Across Severities and Comorbidities Open
View article: Effectiveness of a Maintenance and Reliever Digihaler System in Asthma: 24-Week Randomized Study (CONNECT2)
Effectiveness of a Maintenance and Reliever Digihaler System in Asthma: 24-Week Randomized Study (CONNECT2) Open
The positive results in asthma control in this study after 24 weeks demonstrate the effectiveness of the DS in asthma management.
View article: Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma Open
Rationale: Previous studies investigating the impact of comorbidities on the effectiveness of biologic agents have been relatively small and of short duration and have not compared classes of biologic agents. Objectives: To d…
View article: M15 Quantification of clinical deterioration of asthma based on threshold for SABA use in two studies of the digihaler system
M15 Quantification of clinical deterioration of asthma based on threshold for SABA use in two studies of the digihaler system Open
Background In two studies of the Digihaler System (DS), patients with suboptimally controlled asthma used an albuterol inhaler with an integrated sensor that objectively recorded real-time reliever use. US asthma experts, through a modifie…
View article: M16 Recognizing asthma risk scenarios: individualized inhaler usage and inhalation parameter profiles from an electronic inhaler with integrated sensors
M16 Recognizing asthma risk scenarios: individualized inhaler usage and inhalation parameter profiles from an electronic inhaler with integrated sensors Open
Rationale Suboptimal adherence, errors in inhaler technique, and reliever overuse are risk factors associated with poor asthma outcomes. The Digihaler® electronic inhaler provides objective data on usage and inhalation parameter…
View article: Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry Open
View article: Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR) Open
ClinicalTrials.gov Identifier: NCT03347279 (https://clinicaltrials.gov/ct2/show/NCT03347279).
View article: Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry Open
View article: Comparative effectiveness of <scp>anti‐IL5</scp> and <scp>anti‐IgE</scp> biologic classes in patients with severe asthma eligible for both
Comparative effectiveness of <span>anti‐IL5</span> and <span>anti‐IgE</span> biologic classes in patients with severe asthma eligible for both Open
Background Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma…
View article: Tezepelumab Efficacy By SNOT-22 Score In Patients With Severe, Uncontrolled Asthma And Comorbid Nasal Polyps In NAVIGATOR
Tezepelumab Efficacy By SNOT-22 Score In Patients With Severe, Uncontrolled Asthma And Comorbid Nasal Polyps In NAVIGATOR Open
View article: Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Specific Perennial Allergen Immunoglobulin E Thresholds
Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Specific Perennial Allergen Immunoglobulin E Thresholds Open
View article: Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for both
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for both Open
Background Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of severe adult asthma patients elig…
View article: Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy Open
Around one third of severe HOCS asthma patients did not receive biologics despite a similar high burden of asthma exacerbations as those who initiated a biologic therapy. Other disease characteristics such as eosinophilic phenotype, seriou…
View article: Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma
Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma Open
Introduction/Background: Biomarker-defined clusters of severe asthma patients were previously identified via hierarchical cluster analysis; a cluster of older females with low-to-medium Type 2 (T2) biomarkers was characterized (Denton, E. …
View article: Effectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study (CONNECT1)
Effectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study (CONNECT1) Open
In this study, participants using the RDS had greater odds of clinically meaningful improvements in asthma control versus SoC after 3 months. Further investigation of the potential of the RDS to help improve asthma management is warranted.
View article: Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial
Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial Open
Rationale: There are no pharmacologic agents that modify emphysema progression in patients with chronic obstructive pulmonary disease (COPD). Objectives: To evaluate the efficacy of losartan, an angiotensin receptor blocker, …
View article: Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions
Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions Open
Asthma classifications that can be easily characterized at patient level to ensure accurate diagnosis, predict disease trajectory, and treatment response are required. The current dichotomy of allergic and eosinophilic asthma classificatio…
View article: Eosinophil as a Biomarker of Severity and Clinically Important Asthma Outcomes in Benralizumab Phase III Studies
Eosinophil as a Biomarker of Severity and Clinically Important Asthma Outcomes in Benralizumab Phase III Studies Open
View article: Recent advances in allergic rhinitis
Recent advances in allergic rhinitis Open
Allergic rhinitis affects 20 to 30% of adults in both the United States and Europe and perhaps a somewhat higher percentage of children. In addition to nasal and ocular symptoms directly related to the allergic process, interference of the…
View article: Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease
Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease Open
Rationale: Anxiety is a common comorbidity of chronic obstructive pulmonary disease (COPD) that is associated with higher morbidity and mortality. We evaluated three anxiety screening questionnaires: the Generalized Anxiety Disorder…
View article: Heart Rate Variability Biofeedback Does Not Substitute for Asthma Steroid Controller Medication
Heart Rate Variability Biofeedback Does Not Substitute for Asthma Steroid Controller Medication Open